Design of postremission therapy
LAME-9123 | |
| Intensive consolidation 1* | DNR, 40 mg/m2/d for 4 d |
| VP16, 100 mg/m2/d for 4 d | |
| AraC, 100 mg/m2/d for 4 d | |
| Allogeneic SCT after consolidation 1 | |
| Intensive consolidation 2* | Amsa, 150 mg/m2/d for 3 d |
| IDAC, 1000 mg/m2/12 h for 4 d | |
| L-ASPA, 6000 IU/m2/d for 2 d | |
| Maintenance or not† | |
| ALFA-900024 | |
| Mild consolidation 1 | Amsa, 90 mg/m2/d for 1 d |
| AraC, 120 mg/m2/d for 5 d | |
| No allogeneic SCT in first CR | |
| Intensive consolidation 2‡ | MTZ, 12 mg/m2/d for 3 d |
| VP16, 200 mg/m2/d for 3 d | |
| IDAC, 500 mg/m2/d for 6 d | |
| No maintenance | |
| BGMT-8725 and -9126 | |
| Mild consolidation 1 | DNR, 60 mg/m2/d for 2 d |
| AraC, 100 mg/m2/d for 7 d | |
| Allogeneic SCT after consolidation 1 | |
| Intensive consolidation 2 | DNR, 45 mg/m2/d for 3 d |
| HDAC, 3000 mg/m2/12 h for 4 d | |
| Autologous SCT or maintenance§ | |
| GEOLAM-0127 and -0228 | |
| Allogeneic SCT before consolidation 1 | |
| Intensive consolidation 1 | IDA, 10 mg/m2/d for 2 d or RBZ, 200 mg/m2/d for 2 d |
| HDAC, 3000 mg/m2/12 h for 4 d | |
| Autologous SCT∥ | Amsa, 150 mg/m2/d for 5 d |
| or intensive consolidation 2 | VP16, 100 mg/m2/d for 5 d |
| No maintenance |
LAME-9123 | |
| Intensive consolidation 1* | DNR, 40 mg/m2/d for 4 d |
| VP16, 100 mg/m2/d for 4 d | |
| AraC, 100 mg/m2/d for 4 d | |
| Allogeneic SCT after consolidation 1 | |
| Intensive consolidation 2* | Amsa, 150 mg/m2/d for 3 d |
| IDAC, 1000 mg/m2/12 h for 4 d | |
| L-ASPA, 6000 IU/m2/d for 2 d | |
| Maintenance or not† | |
| ALFA-900024 | |
| Mild consolidation 1 | Amsa, 90 mg/m2/d for 1 d |
| AraC, 120 mg/m2/d for 5 d | |
| No allogeneic SCT in first CR | |
| Intensive consolidation 2‡ | MTZ, 12 mg/m2/d for 3 d |
| VP16, 200 mg/m2/d for 3 d | |
| IDAC, 500 mg/m2/d for 6 d | |
| No maintenance | |
| BGMT-8725 and -9126 | |
| Mild consolidation 1 | DNR, 60 mg/m2/d for 2 d |
| AraC, 100 mg/m2/d for 7 d | |
| Allogeneic SCT after consolidation 1 | |
| Intensive consolidation 2 | DNR, 45 mg/m2/d for 3 d |
| HDAC, 3000 mg/m2/12 h for 4 d | |
| Autologous SCT or maintenance§ | |
| GEOLAM-0127 and -0228 | |
| Allogeneic SCT before consolidation 1 | |
| Intensive consolidation 1 | IDA, 10 mg/m2/d for 2 d or RBZ, 200 mg/m2/d for 2 d |
| HDAC, 3000 mg/m2/12 h for 4 d | |
| Autologous SCT∥ | Amsa, 150 mg/m2/d for 5 d |
| or intensive consolidation 2 | VP16, 100 mg/m2/d for 5 d |
| No maintenance |
SCT indicates stem cell transplantation; DNR, daunorubicin; VP16, etoposide; AraC, cytarabine; Amsa, amsacrine; IDAC, intermediate-dose cytarabine; L-ASPA, L-asparaginase; MTZ, mitoxantrone; HDAC, high-dose cytarabine; IDA, idarubicin; and RBZ, rubidazone.
In infants, postremission therapy was amended in December 1993 for one IDAC cycle followed by allogeneic or autologous HSCT.
Randomization between maintenance therapy or not.
Half-dose VP16 and IDAC in patients aged 50 years or older.
Randomization between autologous SCT or maintenance therapy in the BGMT-87 trial; autologous SCT for all patients in the BGMT-91 trial.
Randomization between autologous SCT and intensive consolidation 2 in the GOELAM-01 trial; intensive consolidation 2 for all patients in the GOELAM-02 trial.